ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Lung Cancer - Radiation Therapy

August 20, 2015
This is a letter in response to the article by Chang and colleagues. The authors point out that only 58 patients were enrolled from 38 centers over 66.3 months, and speculate that this might be due to patients' preference for surgery.
August 20, 2015
This is a letter in response to the article by Chang and colleagues.
August 20, 2015
This is a letter in response to the article by Chang and colleagues. The authors warn to interpret the findings of the original article, that SABR is better tolerated and might lead to improved survival compared to surgery for good risk patients with clinical stage I NSCLC, with caution. They highlight two pitfalls of the original study.
August 20, 2015
This is a letter in response to the article by Chang and colleagues. The authors begin by stating that the data from this study should be graded according to an internationally accepted system, GRADE.
August 19, 2015
This is a letter in response to the article by Chang and colleagues. The authors state that this type of analysis was necessary as it is difficult to conduct a clinical trial that involves new technology.
August 19, 2015
This is the authors' reply to the letters submitted to The Lancet Oncology. They begin by stating that the strength of their analysis was that patients were randomised, thereby avoiding selection bias. With regards to low accrual, one major factor was failure of thoracic surgeons to participate. In addition, stage I NSCLC is relatively uncommon.
May 20, 2015
A pooled analysis of outcomes from two randomized trials involving SBRT or surgery for operable patients with clinical early stage NSCLC was performed. The number of patients was small (58 total) and the follow-up was a median of 35-40 mos.  Overall 3-year survival was better in the SBRT group (95% vs 79%; p=0.037) whereas recurrence free survival di
April 2, 2015
The authors retrospectively reviewed their institutional database to assess outcomes for VATS lobectomy vs SBRT for stage I NSCLC, comparing propensity score-matched groups (41 pairs).  Survival, cancer-specific survival, local recurrence, and distant recurrence were significantly better in the surgical group. 
March 10, 2015
A review of the National Cancer Data Base was undertaken to determine the impact of postoperative radiation therapy on survival for patients with pathologic stage IIIA NSCLC in the setting of adjuvant chemotherapy.
February 21, 2015
Indications for postoperative radiation therapy (PORT) for resected lung cancer are unclear.  This study evaluated outcomes from the National Cancer Data Base 2004-2006, including 2115 patients resected with pathologic N2 NSCLC, of whom  918 (43%) received PORT.  PORT was associated with better median survival (42 vs 38 mos, p=0.048) and was associat

Pages